High Praise, Condemnation for CMS Aduhelm Coverage Plan

Medicare has received a key endorsement of its plan to restrict payment for the controversial Alzheimer’s disease (AD) drug aducanumab (Aduhelm) — but also drew pleas from other groups for more generous reimbursement of the drug, as well as expected similar medications currently in development . The Centers for Medicare & Medicaid Services (CMS) received … Read more